**Targeting Toxic Nuclear RNA Foci
with CRISPR-Cas13
to Treat Myotonic Dystrophy**

Pornthida Poosala^{1,2}, Sean R. Lindley^{1,2}, Kelly M. Anderson^{1,2} and Douglas M. Anderson^{1,2,*}

¹Center for RNA Biology, ²Aab Cardiovascular Research Institute, University of Rochester
School of Medicine and Dentistry, Rochester, New York, U.S.A., 14642

*Corresponding Author:

Douglas M. Anderson: doug_anderson@urmc.rochester.edu

Keywords: DMPK, DM1, CUG, trinucleotide repeat, microsatellite expansion, RNA Foci, MBNL1, muscleblind-like 1, dPspCas13b, crRNA, *hilightR*, *eraseR*

Human monogenetic diseases can arise from the aberrant expansion of tandem nucleotide repeat sequences, which when transcribed into RNA, can misfold and aggregate into toxic nuclear foci¹. Nuclear retention of repeat-containing RNAs can disrupt their normal expression and induce widespread splicing defects by sequestering essential RNA binding proteins. Among the most prevalent of these disorders is myotonic dystrophy type 1 (DM1), a disease occurring from the expression of a noncoding CTG repeat expansion in the 3'UTR of the human *dystrophia myotonica protein kinase* (DMPK) gene^{2,3}. Here we show that RNA-binding CRISPR-Cas13, with a robust non-classical nuclear localization signal, can be efficiently targeted to toxic nuclear RNA foci for either visualization or cleavage, tools we named *hilightR* and *eraseR*, respectively. *HilightR* combines catalytically dead Cas13b (dCas13b) with a fluorescent protein to directly visualize CUG repeat RNA foci in the nucleus of live cells, allowing for quantification of foci number and observation of foci dynamics. *EraseR* utilizes the intrinsic endoribonuclease activity of Cas13b, targeted to nuclear CUG repeat RNA, to disrupt nuclear foci. These studies demonstrate the potential for targeting toxic nuclear RNA foci directly with CRISPR-Cas13 for either the identification or treatment of DM1. The efficient and sequence programmable nature of CRISPR-Cas13 systems will allow for rapid targeting and manipulation of other human nuclear RNA disorders, without the associated risks of genome editing.

Myotonic dystrophy type 1 (DM1) is an autosomal dominant human monogenic disease characterized by progressive myotonia, muscle wasting, cardiac arrhythmias, and cognitive dysfunction⁴. DM1 is the most common form of adult-onset muscular

dystrophy, occurring in roughly 1 in 8,000 individuals⁵. Mutant DMPK mRNAs with greater than ~50 CUG repeats form toxic nuclear RNA foci, which prevent normal DMPK expression and induce widespread defects in alternative splicing and polyadenylation by sequestering members of the muscleblind-like (MBNL) family of RNA binding proteins⁶⁻¹³. Loss of MBNL1 and 2 function account for up to 80% of the observed DM1 phenotype, however, overexpression of MBNL proteins have had limited success rescuing splicing defects and only modest amelioration of muscle function in DM1 mouse models, suggesting a multifactorial cause for DM1 symptoms¹⁴⁻¹⁷. The multitude of dysfunctional pathologies associated with the formation of toxic RNA foci suggests that targeted degradation of CUG expansion (CUG^{exp}) RNA would provide therapeutic benefit to DM1 patients.

Despite intense effort, there are no currently approved therapies designed to treat DM1. Antisense oligonucleotides (ASOs) targeting CUG-repeats have been successfully used to reduce the levels of toxic RNAs and disrupt binding and sequestration of MBNL proteins in animal models^{18,19}. However, significant challenges remain for the delivery of these molecules at therapeutically effective levels in human skeletal muscle. Genome editing approaches using CRISPR-Cas9 DNA endonucleases have been employed to directly edit the DMPK gene locus. However, CRISPR-Cas9 editing at either the 5' or 3' ends of CTG genomic repeats can induce large and uncontrolled sequence deletions, and the use of double guide-RNAs flanking the repeat expansion can lead to frequent sequence inversions, which remain toxic^{20,21}. Since CRISPR-Cas9 approaches for manipulating DNA remain inefficient and controversial due to the risk of germline editing, an alternative approach targeting the repeat RNAs using deactivated Cas9 (dCas9) fused

to an active ribonuclease has recently been shown to be effective in cells²². However, the efficiency of this approach for targeting nuclear CUG^{exp} RNA in DM1 patients could be limited by a number of factors, such as: 1) dCas9 retains affinity for DNA, which could compete for its binding to RNA, 2) the large size of dCas9 fusion proteins may limit their nuclear localization or delivery in vivo, 3) dCas9 utilizes short guide-RNAs which may increase the chance of off-target RNA cleavage and, 4) they require protospacer adjacent motifs (PAM) for efficient binding, which are not present in most human repeat expansion sequences. Thus, significant challenges remain for the development of efficient therapeutic strategies to target toxic nuclear RNAs in DM1 patients.

In contrast, bacterial-derived CRISPR-Cas13 systems bind specifically to RNA and function as endoribonucleases to cleave RNA, bypassing the risk of germline editing that is associated with DNA-binding CRISPR-Cas endonucleases²³⁻²⁵. Single residue mutations within the two nuclease domains of Cas13 generate a catalytically deactivated enzyme (dCas13), which retains programmable RNA binding affinity in mammalian systems without the requirement for PAM sequences for efficient targeting²⁶. Due to their large size and lack of intrinsic localization signals, both Cas9 and Cas13 fusion proteins are inefficiently localized to the mammalian nucleus. In our recent pre-print manuscript describing the adaptation of CRISPR-Cas13 for inducing targeted RNA cleavage and polyadenylation (<https://doi.org/10.1101/531111>), we identified a non-classical nuclear localization signal (NLS) derived from the yeast Ty1 retrotransposon which promotes robust nuclear localization of Cas13. The powerful activity of the Ty1 NLS suggested that efficient targeting of nuclear RNAs could be achieved for either visualization or cleavage using CRISPR-Cas13.

To visualize nuclear RNAs using CRISPR-Cas13, we designed a fusion protein combining the catalytically dead Type VI-B Cas13b enzyme from *Prevotella* sp. P5–125 (dPspCas13b) with either a C-terminal enhanced Green Fluorescent Protein (eGFP) or red fluorescent protein, mCherry (Figure 1A). A 3x FLAG epitope tag (F) and Ty1 nuclear localization sequence (Ty1 NLS) were added to the N-terminus of the dPspCas13b fusion proteins to promote efficient nuclear localization, hereinafter referred to as *hilightR green* or *hilightR red* (Figure 1A). Toxic RNA foci are the cellular hallmark of DM1 and can be induced in many cell types by the expression of transgenes expressing expanded CUG repeats. To mimic the nuclear RNA foci found in patients with DM1, we utilized a vector containing 960 CUG repeats in the human DMPK 3' UTR (DT960) (Figure 1B)²⁷. The DT960 construct is sufficient to recapitulate RNA foci formation in cells and can be detected by Fluorescent In Situ Hybridization (FISH) using an antisense (CAG) repeat probe or with an mCherry-MBNL1 fusion protein (Supplementary Figures 1A and B). To target *hilightR* fusion proteins to CUG repeats, we designed a PspCas13b-compatible crRNA containing an antisense CAG repeat target sequence (CAGx9), which is predicted to hybridize with 9 CUG repeats (Figure 1C). Guided by the CAGx9 repeat crRNA, *hilightR green* and *red* were completely nuclear localized and highlighted nuclear RNA foci generated by the DT960 vector (Figure 1D and Supplementary Figure 1C). In contrast, co-expression of *hilightR* constructs with a non-targeting crRNA resulted in broad, un-localized nuclear fluorescence (Figure 1D and Supplementary Figure 1C).

Nuclear foci labeled with *hilightR green* co-localized with an Alexa Fluor 488-conjugated CAG oligonucleotide probe (AF488-CAGx7), detected using FISH (Figure 2A). Consistent with previous reports, nuclear foci labeled with *hilightR green* co-localized

with MBNL1 protein, detected using an mCherry-MBNL1 fusion protein, and partially co-localized with splicing speckles, detected with an antibody specific for SC-35 (Figure 2B and Supplementary Figure 2). These results demonstrate that *highlightR* accurately targets CUG^{exp} RNA foci.

The efficient nuclear targeting of CRISPR-Cas13 to CUG^{exp} RNA foci suggested it could be a useful for targeted cleavage of toxic CUG^{exp} RNA, using its inherent endoribonuclease activity. Cas13 has been shown to be useful for specific cleavage of mRNA transcripts in mammalian and plant cells^{26,28,29}. To determine if Cas13 endoribonuclease activity is sufficient to cleave CUG^{exp} RNA foci, we modified the *highlightR green* fusion protein by reactivating PspCas13b's catalytic mutations using site directed mutagenesis. Surprisingly, we found that activated *highlightR green* did not significantly reduce the number of RNA foci using the CAGx9 targeting crRNA, compared with a non-targeting guide-RNA (data not shown). However, activated PspCas13b containing the N-terminal Ty1 NLS, but lacking the C-terminal eGFP (herein referred to as *eraseR*), resulted in a significant reduction in the number and intensity of RNA foci, quantified using an mCherry-MBNL1 fusion protein (Figure 3A and B). Since target site flanking sequences can influence Cas13 nuclease activation, we tested CAGx9 crRNAs in two other reading frames (CAGx9-f2 and CAGx9-f3). *EraseR* guided by all three CAGx9 crRNAs resulted in significant reduction in the number and intensity of RNA foci per cell, compared to a non-targeting crRNA (Figure 3A and B). Additionally, catalytically dead PspCas13b containing an N-terminal Ty1 NLS and lacking the C-terminal eGFP did not significantly reduce the number and intensity of RNA foci, quantified using an mCherry

MBNL1 fusion protein (Supplementary Figure 3). These data demonstrate for the first time that CRISPR-Cas13 is sufficient to degrade CUG^{exp} RNA foci.

While there are currently no available treatments for myotonic dystrophies or other human RNA repeat expansion disorders, the rapid development of CRISPR-Cas13 systems offer hope that targeted approaches to treat DM1 will soon be achievable. We have shown that Cas13b, localized by a powerful non-classical Ty1 NLS, can be used to efficiently target nuclear CUG^{exp} RNA foci for either visualization or targeted degradation in mammalian cells. The NLS used in these studies was derived from the yeast Ty1 LTR-retrotransposon (Ty1 NLS), which replicates its genome through a cytoplasmic intermediate³⁰. As opposed to higher eukaryotes in which the nuclear envelope breaks down during cell division, the nuclear envelope in yeast remains intact during cell division and thus Ty1 requires active nuclear import for retrotransposition³¹. Interestingly, quiescent mammalian cells also retain a nuclear envelope, suggesting that the Ty1 NLS may be useful for targeting nuclear RNAs by Cas proteins in non-dividing cells.

The programmable nature of CRISPR-Cas13, through simple modification of crRNA target sequences, allow *highlightR* and *eraseR* to be easily adapted for the study and cleavage of other nuclear RNAs, or other repeat expansion disorders such as myotonic dystrophy type 2 (DM2), amyotrophic lateral sclerosis (ALS), huntington's disease-like 2 (HDL2), spinocerebellar ataxias 8, 31 and 10 (SCA8, -31, -10) and fragile X-associated tremor ataxia syndrome (FXTAS). As with other approaches (ASOs or CRISPR-Cas) targeted to simple repeat sequences, there remains the potential for 'coincidental' cleavage of other human mRNA transcripts which contain these short repeat sequence motifs. Future studies will be necessary to evaluate any potential deleterious impacts

resulting from coincidental cleavage events. Alternatively, directly targeting unique human DMPK transcript sequences for degradation by CRISPR-Cas13 or by other forms of RNA manipulation may offer additional approaches for the treatment of toxic RNA diseases.

REFERENCES

- 1 Wojciechowska, M. & Krzyzosiak, W. J. Cellular toxicity of expanded RNA repeats: focus on RNA foci. *Hum Mol Genet* **20**, 3811-3821, doi:10.1093/hmg/ddr299 (2011).
- 2 Fu, Y. H. *et al.* An unstable triplet repeat in a gene related to myotonic muscular dystrophy. *Science* **255**, 1256-1258 (1992).
- 3 Mahadevan, M. *et al.* Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. *Science* **255**, 1253-1255 (1992).
- 4 Bird, T. D. in *GeneReviews((R))* (eds M. P. Adam *et al.*) (1993).
- 5 Harper, P. S., Brook, J. D. & Newman, E. *Myotonic dystrophy*. 3rd edn, (Saunders, 2001).
- 6 Nakamori, M. *et al.* Splicing biomarkers of disease severity in myotonic dystrophy. *Ann Neurol* **74**, 862-872, doi:10.1002/ana.23992 (2013).
- 7 Kuyumcu-Martinez, N. M. & Cooper, T. A. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. *Prog Mol Subcell Biol* **44**, 133-159 (2006).
- 8 Batra, R. *et al.* Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. *Mol Cell* **56**, 311-322, doi:10.1016/j.molcel.2014.08.027 (2014).
- 9 Brook, J. D. *et al.* Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. *Cell* **68**, 799-808 (1992).

- 10 Martorell, L., Monckton, D. G., Sanchez, A., Lopez De Munain, A. & Baiget, M. Frequency and stability of the myotonic dystrophy type 1 premutation. *Neurology* **56**, 328-335 (2001).
- 11 Harley, H. G. *et al.* Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. *Am J Hum Genet* **52**, 1164-1174 (1993).
- 12 Mankodi, A. *et al.* Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. *Hum Mol Genet* **10**, 2165-2170 (2001).
- 13 Taneja, K. L., McCurrach, M., Schalling, M., Housman, D. & Singer, R. H. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. *J Cell Biol* **128**, 995-1002 (1995).
- 14 Kanadia, R. N. *et al.* A muscleblind knockout model for myotonic dystrophy. *Science* **302**, 1978-1980, doi:10.1126/science.1088583 (2003).
- 15 Lee, K. Y. *et al.* Compound loss of muscleblind-like function in myotonic dystrophy. *EMBO Mol Med* **5**, 1887-1900, doi:10.1002/emmm.201303275 (2013).
- 16 Yadava, R. S. *et al.* MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity. *Hum Mol Genet*, doi:10.1093/hmg/ddz065 (2019).
- 17 Kanadia, R. N. *et al.* Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. *Proc Natl Acad Sci U S A* **103**, 11748-11753, doi:10.1073/pnas.0604970103 (2006).
- 18 Jauvin, D. *et al.* Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice. *Mol Ther Nucleic Acids* **7**, 465-474, doi:10.1016/j.omtn.2017.05.007 (2017).
- 19 Wheeler, T. M. *et al.* Targeting nuclear RNA for in vivo correction of myotonic dystrophy. *Nature* **488**, 111-115, doi:10.1038/nature11362 (2012).
- 20 van Agtmaal, E. L. *et al.* CRISPR/Cas9-Induced (CTGCAG)_n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing. *Mol Ther* **25**, 24-43, doi:10.1016/j.ymthe.2016.10.014 (2017).

- 21 Wang, Y. *et al.* Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9. *Mol Ther* **26**, 2617-2630, doi:10.1016/j.ymthe.2018.09.003 (2018).
- 22 Batra, R. *et al.* Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. *Cell* **170**, 899-912 e810, doi:10.1016/j.cell.2017.07.010 (2017).
- 23 Abudayyeh, O. O. *et al.* C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science* **353**, aaf5573, doi:10.1126/science.aaf5573 (2016).
- 24 Smargon, A. A. *et al.* Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28. *Mol Cell* **65**, 618-630 e617, doi:10.1016/j.molcel.2016.12.023 (2017).
- 25 East-Seletsky, A., O'Connell, M. R., Burstein, D., Knott, G. J. & Doudna, J. A. RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes. *Mol Cell* **66**, 373-383 e373, doi:10.1016/j.molcel.2017.04.008 (2017).
- 26 Cox, D. B. T. *et al.* RNA editing with CRISPR-Cas13. *Science* **358**, 1019-1027, doi:10.1126/science.aag0180 (2017).
- 27 Ho, T. H. *et al.* Muscleblind proteins regulate alternative splicing. *EMBO J* **23**, 3103-3112, doi:10.1038/sj.emboj.7600300 (2004).
- 28 Abudayyeh, O. O. *et al.* RNA targeting with CRISPR-Cas13. *Nature* **550**, 280-284, doi:10.1038/nature24049 (2017).
- 29 Aman, R. *et al.* RNA virus interference via CRISPR/Cas13a system in plants. *Genome Biol* **19**, 1, doi:10.1186/s13059-017-1381-1 (2018).
- 30 Curcio, M. J., Lutz, S. & Lesage, P. The Ty1 LTR-Retrotransposon of Budding Yeast, *Saccharomyces cerevisiae*. *Microbiol Spectr* **3**, MDNA3-0053-2014, doi:10.1128/microbiolspec.MDNA3-0053-2014 (2015).
- 31 Moore, S. P., Rinckel, L. A. & Garfinkel, D. J. A Ty1 integrase nuclear localization signal required for retrotransposition. *Mol Cell Biol* **18**, 1105-1114 (1998).

- 32 Anderson, D. M. *et al.* Severe muscle wasting and denervation in mice lacking the RNA-binding protein ZFP106. *Proc Natl Acad Sci U S A* **113**, E4494-4503, doi:10.1073/pnas.1608423113 (2016).

ACKNOWLEDGEMENTS

DT960 was a gift from Thomas Cooper (Addgene plasmid # 80412; <http://n2t.net/addgene:80412>; RRID: Addgene_80412).

AUTHOR CONTRIBUTIONS

P.P., K.M.A. and D.M.A. designed the experiments. P.P., S.R.L, K.M.A., and D.M.A performed the experiments and analyzed data. P.P., K.M.A., and D.M.A generated the figures and wrote the manuscript.

AUTHOR INFORMATION

The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to D.M.A. (doug_anderson@urmc.rochester.edu).

FIGURE LEGENDS

Figure 1 Development of robust nuclear localized CRISPR-Cas13 fusion proteins for the visualization of toxic RNA foci. **(A)** Design of catalytically dead PspCas13b (dPspCas13b) encoding an N-terminal 3x FLAG and Ty1 NLS and C-terminal eGFP. F – 3xFLAG epitope; NLS – Ty1 nuclear localization sequence; pA – SV40 polyadenylation sequence. **(B)** Diagram depicting the DT960 vector, which expresses a C-terminal genomic fragment of human DMPK (exons 11-15) encoding a 960 CTG repeat expansion in the 3'UTR. **(C)** Design of the CAGx9 crRNA and its predicted hybridization with CUG^{exp} RNA. **(D)** Representative images showing the cellular localization of *hilightR green* guided by either a non-targeting crRNA or the CAGx9 crRNA in COS7 cells expressing CUG^{exp} RNA. Scale bars, 10 μ m.

Figure 2 Co-localization of *hilightR green* with CUG^{exp} RNA foci and MBNL1. **(A)** Immunohistochemistry using an anti-FLAG antibody was used to detect *hilightR red*, targeted with the CAGx9 crRNA, which co-localized with CUG^{exp} RNA detected by FISH with an Alexa Fluor 488 CAGx7 probe. **(B)** *HilightR green* co-localized with mCherry-MBNL1 in COS7 cells expressing CUG^{exp} RNA foci when targeted with the CAGx9 crRNA, but not with a non-targeting crRNA. Scale bars, 10 μ m.

Figure 3 Degradation of toxic RNA foci by catalytically active PspCas13b. **(A)** Co-expression of active PspCas13b encoding a Ty1 NLS (*eraseR*) significantly decreased the number of RNA foci in cells expressing CUG^{exp} RNA, when targeted with all three

CAGx9 crRNAs, detected using mCherry-MBNL1. **(B)** Representative micrographs of cells targeted by *eraseR* showing foci detected by mCherry-MBNL1, which are significantly decreased in number and appear fainter. Scale bars, 10 μ m. ** = p-value < 0.01, *** = p-value < 0.001, **** = p-value < 0.0001.

Figure 2

Figure 3

METHODS

Synthetic DNA and Cloning

The mammalian expression vector containing an N-terminal 3x FLAG and Ty1 NLS fused to dPspCas13b (described previously, <https://doi.org/10.1101/531111>) was modified to encode a C-terminal enhanced Green Fluorescent Protein (eGFP) or red fluorescent protein, mCherry. All crRNAs were designed to be 30 nucleotides in length and start with a 5' G for efficient transcription from the hU6 promoter in pC00043²⁶. The negative control non-targeting crRNA has been previously described²⁶. To generate the mCherry-MBNL expression plasmid, the coding sequence of human MBNL1 was designed and synthesized for assembly as a gBlock (IDT, Integrated DNA Technologies) and cloned into the CS2mCherry mammalian expression plasmid³². Please see Supplementary Table 1 for cloned sequences. All plasmid insert sequences were verified by Sanger sequencing.

Cell Culture, Transient Transfections and Immunohistochemistry

The COS7 cell line was maintained in DMEM supplemented with 10% Fetal Bovine Serum (FBS) with penicillin/streptomycin at 37°C in an atmosphere of 5% CO₂. Briefly, 100,000 cells per well were seeded on glass coverslips in 6-well plates and transiently transfected after 24 hours using Fugene6 (Promega) according to manufacturer's protocol. For *highlightR* experiments, cells were transfected with vectors encoding *highlightR*, crRNA, mCherry-MBNL1, and DT960 in a ratio of 2:2:2:1, and imaged twenty-four hours post-transfection. For *eraseR* experiments, cells were transfected with vectors

encoding *eraseR*, crRNA, mCherry-MBNL1, and DT960 in a ratio of 2:2:2:1, and imaged forty-eight hours post-transfection. For immunohistochemistry, transiently transfected COS7 cells were fixed in 4% formaldehyde in DPBS for 15 minutes, blocked in 3% Bovine Serum Albumin (BSA) and incubated with primary antibodies in 1% BSA for 4 hours at room temperature. Primary antibodies used were anti-FLAG (Sigma, F1864) at 1:1000 and anti-SC-35 (Abcam, ab11826) at 1:1000. Cells were subsequently incubated with an Alexa Fluor 488 or 594 conjugated secondary antibody (Thermofisher) in 1% BSA for 30 minutes at room temperature. Coverslips were mounted using anti-fade fluorescent mounting medium containing DAPI (Vector Biolabs, H-1200) and imaged using confocal microscopy.

Fluorescent In Situ Hybridization (FISH)

Twenty-four hours post-transfection, cells were fixed in ice cold 100% Methanol for 10 minutes at -20°C, then washed 2 times with DPBS and 1 time with Wash Buffer [2X SSC pH 7.0, 10% Formamide]. Cells were subsequently hybridized with probe in Hybridization Buffer [10% Dextran Sulfate, 2X SSC pH7.0, 10% Formamide] with a final probe concentration of 100 nM. Cells were hybridized overnight at 37°C. Cells were then washed one time in Wash Buffer at 37°C for 30 minutes, then mounted with VectaShield with DAPI (Vector Biolabs) on slides and imaged using confocal microscopy. The probe was a 21-mer DNA oligonucleotide (CAGCAGCAGCAGCAGCAGCAG) conjugated with a 5' Alexa Fluor 488 dye and purified using HPLC (IDT, Integrated DNA Technologies).

SUPPLEMENTARY DATA

SUPPLEMENTARY FIGURES

Supplementary Figure 1 Detection of induced CUG^{exp} RNA foci in COS7 cells. **(A)** COS7 cells expressing 960 copies of CUG repeats induced RNA foci as detected using FISH with a CAG repeat antisense probe. AF488 – Alexa Fluor 488. **(B)** Expression of CUG^{exp} RNA induces the localization of MBNL1 to foci, as detected using an mCherry-MBNL1

fusion protein. (C) Localization of dPspCas13b-mCherry (*highlightR red*) guided by either a non-targeting or CAGx9 crRNA in COS7 cells expressing CUG^{exp} RNA. Scale bars, 10 μ m.

Supplementary Figure 2 Co-localization of *highlightR green* with splicing speckles. In agreement with previous reports, CUG^{exp} RNA foci marked by *highlightR green* targeted with a CAGx9 crRNA, co-localized with splicing speckles, as detected using an anti-SC-35 antibody. Scale bars, 10 μ m.

Supplementary Figure 3 Catalytically dead Cas13 (dCas13) does not significantly reduce the number of CUG^{exp} RNA foci. Expression of dPspCas13b targeted with CAGx9 crRNAs does not significantly reduce the number of CUG^{exp} RNA foci per cell, as detected by mCherry-MBNL1. ns - not significant.

SUPPLEMENTARY TABLE 1: Sequences

PspCas13b crRNA target sequences (cloned into pC0043²⁶)

CAGx9

5'–GCAGCAGCAGCAGCAGCAGCAGCAGCAGCA–3'

CAGx9-f2

5'–GAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC–3'

CAGx9-f3

5'–GCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG–3'

QuikChange Site-Directed Mutagenesis primers

PspCas13b A133H

5'–ATGTACAGGGACCTGACCAACCACTACAAGACCTACGAGGAAAAG–3'

PspCas13b A1058H

5'–AAGATCCGGAACGCCTTCGATCACAACAATTACCCCGACAAAGG–3'

hilightR green

3xFLAG-Ty1NLS-dPspCas13b-linker-eGFP

ATG**GACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATG**
ACAAGGGCGGAAACTCAAAGAAAAGGTCACTGGAGGACAACGAAACGGAAATCAAAGTCTCCAG
AGACACCTGGAACACTAAGAACATGCGGTCCCTGGAACCGCCACGAAGCAAGAAACGGATACAT
GGAGGCAACATCCCCGCTCTGGTGGAAAACCAGAAGAAGTACTTTGGCACCTACAGCGTGATGG
CCATGCTGAACGCTCAGACCGTGCTGGACCACATCCAGAAGGTGGCCGATATTGAGGGCGAGCA
GAACGAGAACAACGAGAATCTGTGGTTTCACCCCGTGATGAGCCACCTGTACAACGCCAAGAAC
GGCTACGACAAGCAGCCCGAGAAAACCATGTTTCATCATCGAGCGGCTGCAGAGCTACTTCCCAT
TCCTGAAGATCATGGCCGAGAACCAGAGAGAGTACAGCAACGGCAAGTACAAGCAGAACC
GCGTGGAAAGTGAACAGCAACGACATCTTCGAGGTGCTGAAGCGCGCCTTCGGCGTGCTGAAGATGTAC
AGGGACCTGACCAACGCATACAAGACCTACGAGGAAAAGCTGAACGACGGCTGCGAGTTCCTGA
CCAGCACAGAGCAACCTCTGAGCGGCATGATCAACAATACTACACAGTGGCCCTGCGGAACAT
GAACGAGAGATACGGCTACAAGACAGAGGACCTGGCCTTCATCCAGGACAAGCGGTTCAAGTTC
GTGAAGGACGCCTACGGCAAGAAAAGTCCCAAGTGAATACCGGATTCTTCTGAGCCTGCAGG
ACTACAACGGCGACACACAGAAGAAGCTGCACCTGAGCGGAGTGGGAATCGCCCTGCTGATCTG
CCTGTTCTGAGACAAGCAGTACATCAACATCTTTCTGAGCAGGCTGCCATCTTCTCCAGCTAC
AATGCCAGAGCGAGGAACGGCGGATCATCATCAGATCCTTCGGCATCAACAGCATCAAGCTGC
CCAAGGACCGGATCCACAGCGAGAAGTCCAACAAGAGCGTGGCCATGGATATGCTCAACGAAGT

GAAGCGGTGCCCCGACGAGCTGTTCAACAACACTGTCTGCCGAGAAGCAGTCCCGGTTTCAAGATC
ATCAGCGACGACCACAATGAAGTGCTGATGAAGCGGAGCAGCGACAGATTCGTGCCTCTGCTGC
TGCAGTATATCGATTACGGCAAGCTGTTTCGACCACATCAGGTTCCACGTGAACATGGGCAAGCT
GAGATACCTGCTGAAGGCCGACAAGACCTGCATCGACGGCCAGACCAGAGTCAGAGTGATCGAG
CAGCCCCGTAACGGCTTCGGCAGACTGGAAGAGGCCGAGACAATGCGGAAGCAAGAGAACGGCA
CCTTCGGCAACAGCGGCATCCGGATCAGAGACTTCGAGAACATGAAGCGGGACGACGCCAATCC
TGCCAACTATCCCTACATCGTGGACACCTACACACACTACATCCTGGAAAACAACAAGGTCGAG
ATGTTTATCAACGACAAAGAGGACAGCGCCCCACTGCTGCCCCGTGATCGAGGATGATAGATACG
TGGTCAAGACAATCCCCAGCTGCCGGATGAGCACCTGGAAATTCAGCCATGGCCTTCCACAT
GTTTCTGTTTCGGCAGCAAGAAAACCGAGAAGCTGATCGTGGACGTGCACAACCGGTACAAGAGA
CTGTTCCAGGCCATGCAGAAAGAAGAAGTGACCGCCGAGAATATCGCCAGCTTCGGAATCGCCG
AGAGCGACCTGCCTCAGAAGATCCTGGATCTGATCAGCGGCAATGCCACGGCAAGGATGTGGA
CGCCTTCATCAGACTGACCGTGGACGACATGCTGACCGACACCGAGCGGAGAATCAAGAGATTC
AAGGACGACCGGAAGTCCATTTCGGAGCGCCGACAACAAGATGGGAAAGAGAGGCTTCAAGCAGA
TCTCCACAGGCAAGCTGGCCGACTTCCTGGCCAAGGACATCGTGCTGTTTCAGCCCAGCGTGAA
CGATGGCGAGAACAAGATCACCGGCCTGAACTACCGGATCATGCAGAGCGCCATTGCCGTGTAC
GATAGCGGCGACGATTACGAGGCCAAGCAGCAGTTCAAGCTGATGTTTCGAGAAGGCCCGGCTGA
TCGGCAAGGGCACAACAGAGCCTCATCCATTTCTGTACAAGGTGTTTCGCCCCGAGCATCCCCGC
CAATGCCGTGAGTTCTACGAGCGCTACCTGATCGAGCGGAAGTTCTACCTGACCGGCCTGTCC
AACGAGATCAAGAAAGGCAACAGAGTGATGTGCCCTTCATCCGGCGGGACCAGAACAAGTGGA
AAACACCCGCCATGAAGACCCTGGGCAGAATCTACAGCGAGGATCTGCCCGTGGAAGTGGCCAG
ACAGATGTTTCGACAATGAGATCAAGTCCCACCTGAAGTCCCTGCCACAGATGGAAGGCATCGAC
TTCAACAATGCCAACGTGACCTATCTGATCGCCGAGTACATGAAGAGAGTGCTGGACGACGACT
TCCAGACCTTCTACCAGTGGAACCGCAACTACCGGTACATGGACATGCTTAAGGGCGAGTACGA
CAGAAAGGGCTCCCTGCAGCACTGCTTACCAGCGTGGAAGAGAGAGAAGGCCTCTGGAAAGAG
CGGGCCTCCAGAACAGAGCGGTACAGAAAGCAGGCCAGCAACAAGATCCGCAGCAACCGGCAGA
TGAGAAACGCCAGCAGCGAAGAGATCGAGACAATCCTGGATAAGCGGCTGAGCAACAGCCGGA
CGAGTACCAGAAAAGCGAGAAAGTGATCCGGCGCTACAGAGTGACGAGATGCCCTGCTGTTTCTG
CTGGCCAAAAGACCTGACCGAACTGGCCGATTCGACGGCGAGAGGTTCAAAGTGAAGAAA
TCATGCCCCGACGCCGAGAAGGGAATCCTGAGCGAGATCATGCCCATGAGCTTACCTTCGAGAA
AGGCGGCAAGAAGTACACCATCACAGCGAGGGCATGAAGCTGAAGAACTACGGCGACTTCTTT
GTGCTGGCTAGCGACAAGAGGATCGGCAACCTGCTGGAAGTCTGTTGGCAGCGACATCGTGTTCA
AAGAGGATATCATGGAAGAGTTCAACAAATACGACCAGTGCAGGCCCCGAGATCAGCTCCATCGT
GTTCAACCTGGAAAAGTGGGCCTTCGACACATACCCCGAGCTGTCTGCCAGAGTGGAACGGGAA
GAGAAGGTGGACTTCAAGAGCATCCTGAAAATCCTGCTGAACAACAAGAACATCAACAAAGAGC
AGAGCGACATCCTGCGGAAGATCCGGAACGCCTTCGATGCAAACAATTACCCCGACAAAGGCGT
GGTGGAAATCAAGGCCCTGCCTGAGATCGCCATGAGCATCAAGAAGGCCTTTGGGGAGTACGCC
ATCATGAAGTCGCGAGGCGGTGGAGGTAGTGGAGGGGGAGGATCAACGCGTGTGAGCAAGGGCG
AGGAGCTGTTACCGGGGTGGTGCCATCCTGGTTCGAGCTGGACGGCGACGTAAACGGCCACAA
GTTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTTCATC
TGCAACACCGGCAAGCTGCCCCGTGCCCTGGCCACCTCGTGACCACCTGACCTACGGCGTGC
AGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGA
AGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACAGCCACAACGTCTATATCATGGC
CGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGC

GTGCAGCTCGCCGACCACTACCAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCCC
ACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACAT
GGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG
TAA

3xFLAG-Ty1NLS-dPspCas13b-linker-eGFP

MDYKDHDGDYKDHDIDYKDDDDKGGNSKKRSLEDNETEIKVSRDTWNTKNMRSLEPPRSKKRIH
GGNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEQNNENNENLWFHPVMSHLYNAKN
GYDKQPEKTMFIIERLQSYFPFLKIMAENQREYSNGKYKQNRVEVNSNDIFEVLKRAFGVLKMY
RDLTNAYKTYEEKLNDGCEFLTSTEQPLSGMINNYTVALRNMNERYGYKTEDLAFIQDKRFKF
VKDAYGKKKSQVNTGFFLSLQDYNGDTQKKLHLSGVGIALLICFLDKQYINIFLSRLPIFFSY
NAQSEERRIIIRSFINSIKLPKDRIHSEKSNKSVAMDMLEVKRCPDELFTTLSAEKQSRFRI
ISDDHNEVLMKRSSDRFVPLLLQYIDYGKLFDHIRFHVNMGKLYLLKADKTCIDGQTRVRVIE
QPLNGFGRLEEAEATMRKQENGTFGNSGIRIRDFENMKRDDANPANYPIVDITYTHYLENNKVE
MFINDKEDSAPLLPVIEDDRYVVKTIPTSCRMSTLEIPAMAFHMFLLFGSKKTEKLIVDVHNRKYR
LFQAMQKEEVTAENIASFGIAESDLPQKILDLISGNAHGKDVDAFIRLTVDDMLTDTERRIKRF
KDDRKSIRSADNMKGKRGFKQISTGKLADFLAKDIVLFQPSVNDGENKITGLNYRIMQSAIAVY
DSGDDYEAKQQFKLMFEKARLIGKGTTEPHPLYKVFARSIPANAVEFYERYLIERKFYLTGLS
NEIKKGNRVDVPFIRRDQNKWKTPAMKTLGRIYSEDLVELPRQMFNDNEIKSHLKSLLPQMEGID
FNNANVTYLIAEYMKRVLDDDFQTFYQWNRNYRYMDMLKGEYDRKGSLLQHCFTSVEEREGLWKE
RASRTERYRKQASNKIRSNRQMRNASSEIETILDKRLSNSRNEYQKSEKVIIRRYRVQDALLFL
LAKKTLTELADFDGERFKLKEIMPDAEKILSEIMPMSFTFEKGGKTYTITSEGMKLNKYGDF
VLASDKRIGNLLELVGSDIVSKEDIMEEFNKYDQCRPEISSIVFNLEKWAFTYPELSARVDRE
EKVDFKSILKILLNNKNINKEQSDILRKIRNAFDANNYPDKGVVEIKALPEIAMSIKKAFFEYA
IMKSRGGGGSGGGGSTRVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGLTLKFI
CTTGKLPVPWPTLVTTLTYGVCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAE
VKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNNSHNVYIMADKQKNGIKVNFKIRHNIEDGS
VQLADHYQQNTPIGDGPVLLPDNHVLSLTSQALSADPNEKRDHMLLEFVTAAGITLGMDELYK*

*

highlightR red

3xFLAG-Ty1NLS-dPspCas13b-linker-mCherry

ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATG
ACAAGGGCGGAAACTCAAAGAAAAGGTCACTGGAGGACAACGAAACGGAAATCAAAGTCTCCAG
AGACACCTGGAACACTAAGAACATGCGGTCCCTGGAACCGCCACGAAGCAAGAAACGGATACAT
GGAGGCAACATCCCCGCTCTGGTGGAACAAACGAGAAGTACTTTGGCACCTACAGCGTGATGG
CCATGCTGAACGCTCAGACCGTGCTGGACCACATCCAGAAGGTGGCCGATATTGAGGGCGAGCA
GAACGAGAACAACGAGAATCTGTGGTTTCACCCCGTGATGAGCCACCTGTACAACGCCAAGAAC
GGCTACGACAAGCAGCCCGAGAAAACCATGTTTCATCATCGAGCGGCTGCAGAGCTACTTCCCAT
TCCTGAAGATCATGGCCGAGAACCAGAGAGAGTACAGCAACGGCAAGTACAAGCAGAACCAGCT
GGAAGTGAACAGCAACGACATCTTCGAGGTGCTGAAGCGCGCCTTCGGCGTGCTGAAGATGTAC
AGGGACCTGACCAACGCATACAAGACCTACGAGGAAAAGCTGAACGACGGCTGCGAGTTCCTGA
CCAGCACAGAGCAACCTCTGAGCGGCATGATCAACAATACTACACAGTGGCCCTGCGGAACAT
GAACGAGAGATACGGCTACAAGACAGAGGACCTGGCCTTCATCCAGGACAAGCGGTTCAAGTTC

GTGAAGGACGCCTACGGCAAGAAAAAGTCCCAAGTGAATACCGGATTCTTCCTGAGCCTGCAGG
 ACTACAACGGCGACACACAGAAGAAGCTGCACCTGAGCGGAGTGGGAATCGCCCTGCTGATCTG
 CCTGTTCTGAGCAAGCAGTACATCAACATCTTTCTGAGCAGGCTGCCATCTTCTCCAGCTAC
 AATGCCCAGAGCGAGGAACGGCGGATCATCATCAGATCCTTCGGCATCAACAGCATCAAGCTGC
 CCAAGGACCGGATCCACAGCGAGAAGTCCAACAAGAGCGTGGCCATGGATATGCTCAACGAAGT
 GAAGCGGTGCCCCGACGAGCTGTTCAACAACACTGTCTGCCGAGAAGCAGTCCCGGTTTCAAGATC
 ATCAGCGACGACCACAATGAAGTGTGATGAAGCGGAGCAGCGACAGATTCTGTCCTCTGCTGC
 TGCAGTATATCGATTACGGCAAGCTGTTGACACATCAGGTTCCACGTGAACATGGGCAAGCT
 GAGATACCTGCTGAAGGCCGACAAGACCTGCATCGACGGCCAGACCAGAGTCAGAGTGATCGAG
 CAGCCCCTGAACGGCTTCGGCAGACTGGAAGAGGCCGAGACAATGCGGAAGCAAGAGAACGGCA
 CCTTCGGCAACAGCGGCATCCGGATCAGAGACTTCGAGAACATGAAGCGGGACGACGCCAATCC
 TGCCAACTATCCCTACATCGTGGACACCTACACACACTACATCCTGGAAAACAACAAGGTCGAG
 ATGTTTATCAACGACAAAGAGGACAGCGCCCCACTGCTGCCCGTGATCGAGGATGATAGATACG
 TGGTCAAGACAATCCCCAGCTGCCGGATGAGCACCTGGAAATTCCAGCCATGGCCTTCCACAT
 GTTTCTGTTCCGGCAGCAAGAAAACCGAGAAGCTGATCGTGGACGTGCACAACCGGTACAAGAGA
 CTGTTCCAGGCCATGCAGAAAGAAGAAGTGACCGCCGAGAATATCGCCAGCTTCGGAATCGCCG
 AGAGCGACCTGCCTCAGAAGATCCTGGATCTGATCAGCGGCAATGCCACGGCAAGGATGTGGA
 CGCCTTCATCAGACTGACCGTGGACGACATGCTGACCGACACCGAGCGGAGAATCAAGAGATTC
 AAGGACGACCGGAAGTCCATTTCGGAGCGCCGACAACAAGATGGGAAAGAGAGGCTTCAAGCAGA
 TCTCCACAGGCAAGCTGGCCGACTTCTGGCCAAGGACATCGTGCTGTTTCAGCCAGCGTGAA
 CGATGGCGAGAACAAGATCACCGGCCTGAACTACCGGATCATGCAGAGCGCCATTGCCGTGTAC
 GATAGCGGCGACGATTACGAGGCCAAGCAGCAGTTCAAGCTGATGTTTCGAGAAGGCCCGGCTGA
 TCGGCAAGGGCACAACAGAGCCTCATCCATTTCTGTACAAGGTGTTTCGCCCGCAGCATCCCCGC
 CAATGCCGTGCGAGTTCTACGAGCGCTACCTGATCGAGCGGAAGTTCTACCTGACCGGCCTGTCC
 AACGAGATCAAGAAAGGCAACAGAGTGATGTGCCCTTCATCCGGCGGGACCAGAACAAAGTGGA
 AAACACCCGCCATGAAGACCCTGGGCAGAATCTACAGCGAGGATCTGCCCGTGGAAGTGCACG
 ACAGATGTTTCGACAATGAGATCAAGTCCCACCTGAAGTCCCTGCCACAGATGGAAGGCATCGAC
 TTCAACAATGCCAACGTGACCTATCTGATCGCCGAGTACATGAAGAGAGTGCTGGACGACGACT
 TCCAGACCTTCTACCAGTGGAACCGCAACTACCGGTACATGGACATGCTTAAGGGCGAGTACGA
 CAGAAAGGGCTCCCTGCAGCACTGCTTACCAGCGTGGAAGAGAGAGAAGGCCTCTGGAAAGAG
 CGGGCCTCCAGAACAGAGCGGTACAGAAAGCAGGCCAGCAACAAGATCCGCAGCAACCGGCAGA
 TGAGAAACGCCAGCAGCGAAGAGATCGAGACAATCCTGGATAAGCGGCTGAGCAACAGCCGAA
 CGAGTACCAGAAAAGCGAGAAAGTGATCCGGCGCTACAGAGTGAGGATGCCCTGCTGTTTCTG
 CTGGCCAAAAAGACCCTGACCGAACTGGCCGATTTTCGACGGCGAGAGGTTCAAAGTAAAGAAA
 TCATGCCCGACGCCGAGAAGGGAATCCTGAGCGAGATCATGCCCATGAGCTTACCTTCGAGAA
 AGGCGGCAAGAAGTACACCATCACAGCGAGGGCATGAAGCTGAAGAACTACGGCGACTTCTTT
 GTGCTGGCTAGCGACAAGAGGATCGGCAACCTGCTGGAAGTCTGAGGCGAGCATCGTGTTCA
 AAGAGGATATCATGGAAGAGTTCAACAAATACGACCAGTGAGGCCCCGAGATCAGCTCCATCGT
 GTTCAACCTGGAAAAGTGGGCCTTCGACACATACCCGAGCTGTCTGCCAGAGTGGAACGGGAA
 GAGAAGGTGGACTTCAAGAGCATCCTGAAAATCCTGCTGAACAACAAGAATCAACAAGAGC
 AGAGCGACATCCTGCGGAAGATCCGGAACGCCCTTCGATGCAACAATTACCCCGACAAAGGCGT
 GGTGGAATCAAGGCCCTGCCTGAGATCGCCATGAGCATCAAGAAGGCCTTTGGGGAGTACGCC
 ATCATGAAGTTCGCGAGGCGGTGGAGGTAGTGGAGGGGGAGGATCAACGCGTGTAGCAAGGGCG
 AGGAGGATAACATGGCCATCATCAAGGAGTTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGT
 GAACGGCCACGAGTTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCTACGAGGGCACCCAGACC
 GCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCTGGGACATCCTGTCCCCTCAGT

TCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTC
CTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACCTCGAGGACGGCGGCGTGGTGACCGTG
ACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACT
TCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGAT
GTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGC
CACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGACGCTGCCCGGCGCCT
ACAACGTCAACATCAAGTTGGACATCACCTCCACAACGAGGACTACACCATCGTGGAACAGTA
CGAACGCGCCGAGGGCCGCACTCCACCGGCGGCATGGACGAGCTGTACAAGTAGTAA

3xFLAG-Ty1NLS-dPspCas13b-linker-eGFP

MDYKDHDGDYKDHDIDYKDDDDKGGNSKKRSLLEDNETEIKVSRDTWNTKNMRSLEPPRSKKRIH
GGNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEQNENNENLWFHPVMSHLYNAKN
GYDKQPEKTMFIERLQSYFPFLKIMAENQREYSNGKYKQNRVEVNSNDIFEVLKRAFGVLKMY
RDLTNAYKTYEEKLNDGCEFLTSTEQPLSGMINNYTVALRNMNERYGYKTEDLAFIQDKRFKF
VKDAYGKKKSQVNTGFFLSLQDYNGDTQKKLHLSGVGIALLICFLDKQYINIFLSRLPIFSSY
NAQSEERRIIIRSFINSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQSRFRI
ISDDHNEVLMKRSSDRFVPLLLQYIDYGKLFDFHIFHVMGKLYLLKADKTCIDGQTRVRVIE
QPLNGFGRLEEAEATMRKQENGTFGNSGIRIRDFENMKRDDANPANYPIVDITYTHYLENNKVE
MFINDKEDSAPLLPVIEDDRYVVKTIPTSCRMSTLEIPAMAFHMFLLFGSKKTEKLIVDVHNRKYR
LFQAMQKEEVTAENIASFGIAESDLQKILDLISGNAHGKDVDAFIRLTVDDMLTDTERRIKRF
KDDRKSIRSADNKMGRGFKQISTGKLADFLAKDIVLFQPSVNDGENKITGLNYRIMQSAIAVY
DSGDDYEAKQQFKLMFEKARLIGKGTTEPHFPLYKVFARSIPANAVEFYERYLIERKFYLTGLS
NEIKKGNRVDVPFIRRDQNKWKTTPAMKTLGRIYSEDLVELPRQMFNDNEIKSHLKSLLPQMEGID
FNNANVTYLIAEYMKRVLDDDFQTFYQWNRNYRYMDMLKGEYDRKGSLLQHCFTSVEEREGLWKE
RASRTERYRKQASNKIRSNRQMRNASSEIETILDKRLSNSRNEYQKSEKVIRRYRVQDALLFL
LAKKTLTELADFDGERFKLKEIMPDAEKILSEIMPMSFTFEKGGKKTITSEGMLKKNYGDFF
VLASDKRIGNLLELVGSDIVSKEDIMEEFNKYDQCRPEISSIVFNLEKWAFDTYPELSARVDRE
EKVDFKSILKILLNNKNINKEQSDILRKIRNAFDANNYPDKGVVEIKALPEIAMSIIKAFGEYA
IMKSRGGGSGGGGSTRVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQT
AKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLLKLSFPEGFKWERVMNFEDGGVTV
TQDSSLQDGEFIYKVKLRGTNFPDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDG
HYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK**

CS2-mCherry-MBNL1

mCherry-MBNL1

ATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGC
ACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCTA
CGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGAC
ATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCG
ACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACCTCGAGGACGG
CGGCGTGGTGACCGTGACCCAGGACTCCTCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAG
CTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGG

CCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGAA
GCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTG
CAGCTGCCCCGGCGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACA
CCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTA
CAAGGGGAATTCAAGGCCTCTCGAGGCAGTCTCTGTAACACCAATTAGGGATACCAAATGGCTG
ACGCTGGAGGTATGCCGAGAGTTTCAACGCGGAACCTGTAGTCGCCCTGATACGGAGTGCAAGT
TTGCCCCACCCCTCTAAGTCTTGCCAAGTAGAGAATGGGAGAGTCATCGCTTGCTTCGACAGTCT
TAAAGGCCGATGTTACGGGAAAACCTGCAAATATCTTCACCCGCCGCCACATCTCAAAACTCAG
CTTGAGATCAACGGTCGGAACAACCTTATCCAACAGAAAAATATGGCTATGTTGGCGCAGCAGA
TGCAGCTTGCAAATGCTATGATGCCCGGTGCACCTTTGCAACCGGTTCCAATGTTCTCAGTGGC
TCCATCCCTCGCAACAAATGCCTCCGCAGCGGCTTTTAACCCGTACCTCGGCCCCCGTATCCCCA
TCCCTTGTCGCCGCGGAGATACTTCCGACGGCACCCATGTTGGTTACAGGCAATCCAGGGGTAC
CCGTACCCGCGGCAGCGGCCGCTGCGGCGCAAAAACCTTATGCGGACAGATCGGCTCGAAGTCTG
TAGAGAATATCAAAGGGGTAACGTGAACAGGGGGGAAAACGACTGCAGATTGCTCACCCAGCG
GATAGTACAATGATCGACACGAATGACAACACCGTTACCGTATGCATGGACTACATTAAGGGCC
GCTGCAGCAGAGAGAAGTGCAAATACTTTACCCACCCGCCCATCTGCAAGCCAAAATCAAGGC
GGCTCAATACCAAGTCAATCAAGCGGCGGCCGCTCAAGCCGCAGCCACTGCGGCAGCAATGGGT
ATCCCGCAAGCCGTTCTTCCCCCTCTCCCAAAGCGACCGGCCCTCGAAAAAACCAATGGAGCTA
CCGCCGTCTTCAATACGGGCATCTTCCAGTACCAACAAGCCTTGGCTAATATGCAACTTCAACA
ACACACAGCGTTCTTGCCACCAGGATCTATCCTTTGCATGACGCCAGCCACGAGTGTGGTGCC
ATGTTTACGGTGCGACGCCAGCGACTGTATCTGCGGCTACTACGTCCGCAACATCCGTTCCGT
TTGCCGCGACTGCCACGGCAAATCAAATACCGATAATTAGCGCAGAACACTTGACGAGCCACAA
ATACGTCACTCAAATGTAG

mCherry-MBNL1

MVSKGEEDNMAIIKEFMRFKVMHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWD
ILSPQFMYGSKAYVKHPADIPDYKLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVK
LRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPV
QLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDEL YKGNRPLEAVSVTPIRDTKWL
TLEVCREFRQGTCSRPDTECKFAHPSKSCQVENGRVIACFDSLKGRCsRENCKYLHPPPHLKTQ
LEINGRNLIQKQNMAMLAQQMQLANAMMPGAPLQPVPMFSVAPSLATNASAAAFNPYLGVPSP
SLVPAEILPTAPMLVTGNPGVPVPAAAAAAAQKLMRTDRLEVCREYQRGNCNRGENDCRFAHPA
DSTMIDTNDNTVTVCM DYIKGRCSREKCKYFHPPAHLQAKIKAAQYQVNQAAAAQAAATAAMG
IPQAVLPPLPKRPAL EKTNGATAVFNTGIFQYQALANMQLQHTAFLPPGSILCMT PATSVVP
MVHGATPATVSAATTSATSV PFAATATANQIPIISA EHLTSHKYVTQM*

eraseR

3xFLAG-Ty1NLS-PspCas13b

ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATG
ACAAGGGCGGAAACTCAAAGAAAAGGTCACTGGAGGACAACGAAACGGAAATCAAAGTCTCCAG
AGACACCTGGAACACTAAGAACATGCGGTCCCTGGAACCGCCACGAAGCAAGAAACGGATACAT
GGAGGCAACATCCCCGCTCTGGTGGAAAACGAGAAGAAGTACTTTGGCACCTACAGCGTGATGG
CCATGCTGAACGCTCAGACCGTGCTGGACCACATCCAGAAGGTGGCCGATATTGAGGGCGAGCA
GAACGAGAACACGAGAATCTGTGGTTTCACCCCGTGATGAGCCACCTGTACAACGCCAAGAAC

GGCTACGACAAGCAGCCCGAGAAAACCATGTTTCATCATCGAGCGGCTGCAGAGCTACTTCCC
 TCCTGAAGATCATGGCCGAGAACCAGAGAGAGTACAGCAACGGCAAGTACAAGCAGAACC
 GCGT GGAAGTGAACAGCAACGACATCTTCGAGGTGCTGAAGCGCGCCTTCGGCGTGCTGAAGATGTAC
 AGGGACCTGACCAACCACTACAAGACCTACGAGGAAAAGCTGAACGACGGCTGCGAGTTCCTGA
 CCAGCACAGAGCAACCTCTGAGCGGCATGATCAACAACCTACTACACAGTGGCCCTGCGGAACAT
 GAACGAGAGATACGGCTACAAGACAGAGGACCTGGCCTTCATCCAGGACAAGCGGTTCAAGTTC
 GTGAAGGACGCCTACGGCAAGAAAAAGTCCCAAGTGAATACCGGATTCTTCCTGAGCCTGCAGG
 ACTACAACGGCGACACACAGAAGAAGCTGCACCTGAGCGGAGTGGGAATCGCCCTGCTGATCTG
 CCTGTTCTGGACAAGCAGTACATCAACATCTTTCTGAGCAGGCTGCCATCTTCTCCAGCTAC
 AATGCCCAGAGCGAGGAACGGCGGATCATCATCAGATCCTTCGGCATCAACAGCATCAAGCTGC
 CCAAGGACCGGATCCACAGCGAGAAGTCCAACAAGAGCGTGGCCATGGATATGCTCAACGAAGT
 GAAGCGGTGCCCCGACGAGCTGTTCAACAACCTGTCTGCCGAGAAGCAGTCCCGGTTTCAAGATC
 ATCAGCGACGACCACAATGAAGTGTGATGAAGCGGAGCAGCGACAGATTCTGTCCTCTGCTGC
 TGCAGTATATCGATTACGGCAAGCTGTTTCGACCACATCAGGTTCCACGTGAACATGGGCAAGCT
 GAGATACCTGCTGAAGGCCGACAAGACCTGCATCGACGGCCAGACCAGAGTCAGAGTGATCGAG
 CAGCCCCTGAACGGCTTCGGCAGACTGGAAGAGGCCGAGACAATGCGGAAGCAAGAGAACGGCA
 CCTTCGGCAACAGCGGCATCCGGATCAGAGACTTCGAGAACATGAAGCGGGACGACGCCAATCC
 TGCCAACTATCCCTACATCGTGGACACCTACACACACTACATCCTGGAAAACAACAAGGTCGAG
 ATGTTTATCAACGACAAAGAGGACAGCGCCCCACTGCTGCCCGTGATCGAGGATGATAGATACG
 TGGTCAAGACAATCCCCAGCTGCCGGATGAGCACCTGGAAATTCAGCCATGGCCTTCCACAT
 GTTTCTGTTTCGGCAGCAAGAAAACCGAGAAGCTGATCGTGGACGTGCACAACCGGTACAAGAGA
 CTGTTCCAGGCCATGCAGAAAGAAGAAGTGACCGCCGAGAATATCGCCAGCTTCGGAATCGCCG
 AGAGCGACCTGCCTCAGAAGATCCTGGATCTGATCAGCGGCAATGCCACGGCAAGGATGTGGA
 CGCCTTCATCAGACTGACCGTGGACGACATGCTGACCGACACCGAGCGGAGAATCAAGAGATTC
 AAGGACGACCGGAAGTCCATTTCGAGCGCCGACAACAAGATGGGAAAGAGAGGCTTCAAGCAGA
 TCTCCACAGGCAAGCTGGCCGACTTCCTGGCCAAGGACATCGTGCTGTTTCAGCCAGCGTGAA
 CGATGGCGAGAACAAAGATCACCGGCCTGAACTACCGGATCATGCAGAGCGCCATTGCCGTGTAC
 GATAGCGGCGACGATTACGAGGCCAAGCAGCAGTTCAAGCTGATGTTTCGAGAAGGCCCGGCTGA
 TCGGCAAGGGCACAACAGAGCCTCATCCATTTCTGTACAAGGTGTTTCGCCCGCAGCATCCCCGC
 CAATGCCGTGCGAGTTCTACGAGCGCTACCTGATCGAGCGGAAGTTCTACCTGACCGGCCTGTCC
 AACGAGATCAAGAAAGGCAACAGAGTGATGTGCCCTTCATCCGGCGGGACCAGAACAAAGTGGA
 AAACACCCGCCATGAAGACCTGGGCAGAATCTACAGCGAGGATCTGCCCGTGGAAGTGGCCAG
 ACAGATGTTTCGACAATGAGATCAAGTCCACCTGAAGTCCCTGCCACAGATGGAAGGCATCGAC
 TTCAACAATGCCAACGTGACCTATCTGATCGCCGAGTACATGAAGAGAGTGCTGGACGACGACT
 TCCAGACCTTCTACAGTGGAACCGCAACTACCGGTACATGGACATGCTTAAGGGCGAGTACGA
 CAGAAAGGGCTCCCTGCAGCACTGCTTCACCAGCGTGGAAGAGAGAGAAGGCCTCTGGAAAGAG
 CGGGCCTCCAGAACAGAGCGGTACAGAAAGCAGGCCAGCAACAAGATCCGCAGCAACCGGCAGA
 TGAGAAACGCCAGCAGCGAAGAGATCGAGACAATCCTGGATAAGCGGCTGAGCAACAGCCGGAA
 CGAGTACCAGAAAAGCGAGAAAGTGATCCGGCGCTACAGAGTGCAAGATGCCCTGCTGTTTCTG
 CTGGCCAAAAAGACCTGACCGAACTGGCCGATTTTCGACGGCGAGAGGTTCAAAGTGAAGAAA
 TCATGCCCGACGCCGAGAAGGGAATCCTGAGCGAGATCATGCCCATGAGCTTACCTTCGAGAA
 AGGCGGCAAGAAGTACACCATCACAGCGAGGGCATGAAGCTGAAGAACTACGGCGACTTCTTT
 GTGCTGGCTAGCGACAAGAGGATCGGCAACCTGCTGGAAGTCTGTTGGCAGCGACATCGTGTCCA
 AAGAGGATATCATGGAAGAGTTCAACAAATACGACCAGTGCAGGCCCCGAGATCAGCTCCATCGT
 GTTCAACCTGGAAAAGTGGGCCTTCGACACATACCCCGAGCTGTCTGCCAGAGTGGAACGGGAA
 GAGAAGGTGGACTTCAAGAGCATCCTGAAAATCCTGCTGAACAACAAGAACATCAACAAGAGC

AGAGCGACATCCTGCGGAAGATCCGGAACGCCTTCGATCACAACAATTACCCCGACAAAGGCGT
GGTGGAATCAAGGCCCTGCCTGAGATCGCCATGAGCATCAAGAAGGCCTTTGGGGAGTACGCC
ATCATGAAGTAGTAA

3xFLAG-Ty1NLS-PspCas13b

MDYKDHDGDYKDHDIDYKDDDDKGGNSKKRSLEDNETEIKVSRDTWNTKNMRSLEPPRSKKRIH
GGNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEQNENNENLWFHPVMSHLYNAKN
GYDKQPEKTMFIIERLQSYFPFLKIMAENQREYSNGKYQNRVEVNSNDIFEVLKRAFGVLKMY
RDLTNHYKTYEEKLNDGCEFLTSTEQPLSGMINNYTVALRNMNERYGYKTEDLAFIQDKRFKF
VKDAYGKKKSQVNTGFFLSLDYNGDTQKKLHLSGVGIALLICLFLDKQYINIFLSRLPIFSSY
NAQSEERRIIIRSFINSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQSRFRI
ISDDHNEVLMKRSSDRFVPLLLQYIDYGKLFDHIRFHVNMGKLRYLLKADKTCIDGQTRVRVIE
QPLNGFGRLEEAETMRKQENGTFGNSGIRIRDFENMKRDDANPANYPIVDYTHYILENNKVE
MFINDKEDSAPLLPVIEDDRYVVKTIPTSCRMSTLEIPAMAFHMFLLFGSKKTEKLIVDVHNRYKR
LFQAMQKEEVTAENIASFGIAESDLPQKILDLISGNAHGKDVDADFIRLTVDMLTDTERRIKRF
KDDRKSIRSADNKMGRGFKQISTGKLADFLAKDIVLFQPSVNDGENKITGLNYRIMQSAIAVY
DSGDDYEAKQQFKLMFEKARLIGKGTTEPHPFYKVFARSIPANAVEFYERYLIERKFYLTGLS
NEIKKGNRVDVPFIRRDQNKWKTPAMKTLGRIYSEDLPVELPRQMFNDNEIKSHLKSLLPQMEGID
FNNANVTYLIAEYMKRVLDDDFQTFYQWNRNYRYMDMLKGEYDRKGSLLQHCFTSVEEREGLWKE
RASRTERYRKQASNKIRSNRQMRNASSEIEIETILDKRLSNSRNEYQKSEKVIIRRYRVQDALLFL
LAKKTLTELADFDGERFKLKEIMPDAEKGILSEIMPMSFTFEKGGKKYTTITSEGMKLKNYGDF
VLASDKRIGNLLELVGSDIVSKEDIMEEFNKYDQCRPEISSIVFNLEKWAFTYPELSARVDRE
EKVDFKSILKILLNNKNINKEQSDILRKIRNAFDHNNYPDKGVVEIKALPEIAMSIKKAFFEYA
IMK**